Company Overview and News

 
Resverlogix Announces Voting Results from the 2018 Annual and Special Meeting of Shareholders

2018-09-12 globenewswire
CALGARY, Alberta, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual and Special Meeting of Shareholders (the “Meeting”) in Calgary, Alberta. A total of 126,864,830 shares (approximately 71.50% of outstanding common shares) were represented in person or by proxy.
RVXCF RVX

 
Resverlogix Announces $26 Million Private Placement

2018-08-30 globenewswire
CALGARY, Alberta, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today it has closed a private placement of approximately 10.4 million equity units at a price of $2.50 per unit for gross proceeds of approximately $26 million (US$20 million), based on an agreed discount to the 5-day volume weighted average price of the Company’s shares between July 30 and August 3, 2018.
RVXCF RVX

 
Resverlogix Supports Epigenetics Satellite Symposium and Provides Oral Presentation on Apabetalone at the European Society of Cardiology Congress 2018 in Munich

2018-08-22 globenewswire
Key Opinion Leaders gather to discuss: LDL-c: Done Deal, Next Epigenetics? Dr. Ewelina Kulikowski of Resverlogix to present data on the effect of apabetalone on vascular inflammation
RVXCF RVX

 
Resverlogix Intends to Pursue U.S. Listing

2018-07-31 globenewswire
CALGARY, Alberta, July 31, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it intends to pursue a listing of its common shares in the United States. Accordingly, if necessary in order to comply with stock exchange minimum share price requirements and in connection with any future equity financing associated therewith, the Company intends to request shareholder approval for a consolidation of the Company’s common shares at an annual and special meeting of shareholders of the Company (the “Meeting”) to be held on September 12, 2018.
RVXCF RVX

 
Resverlogix Announces Upcoming Presentations at Clinical Trials in Alzheimer’s Disease (CTAD) Asia and Alzheimer’s Association International Conference (AAIC)

2018-07-17 globenewswire
CALGARY, Alberta, July 17, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today that it has been awarded two presentations at the Clinical Trials in Alzheimer’s Disease (CTAD) Asia conference in Shanghai, China. Dr. Jeffrey Cummings, Founding Director of the Cleveland Clinic Lou Ruvo Brain Health Center at Las Vegas, will present an oral communication titled, “Cognitive Evaluation of Treatment Effects of the Bromodomain and Extra-terminal Inhibitor Apabetalone; Design and Baseline Data of the Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial” which will highlight the design and baseline characteristics of a prespecified substudy of cognition in elderly patients in the Company’s ongoing phase 3 BETonMACE clinical trial.
RVXCF RVX

7
Hemostemix Formalizes World-Class Scientific Advisory Board

2018-07-05 globenewswire
CALGARY, Alberta, July 05, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX-V:HEM) is pleased to announce the formalization of its Scientific Advisory Board (“SAB”). Members of the SAB are all leaders in their fields of expertise, which span biochemistry, molecular biology, genomics and medicine. The mandate of the Scientific Advisory Board will be to serve as a strategic resource for Hemostemix to advise on research and development initiatives surrounding its stem cell technology product pipeline and the furtherance of Hemostemix’s clinical pipeline and support the Company’s overall mission.
ABT RVXCF RVX ABT

 
Resverlogix Announces FDA Confirmation Regarding Filing Pathway for Apabetalone

2018-06-14 globenewswire
CALGARY, Alberta, June 14, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has received confirmation from the U.S. Food and Drug Administration (“FDA”) that BETonMACE, Resverlogix’s on-going Phase 3 study, if successful, is likely to support the filing and approval of a New Drug Application (“NDA”). The statistical analysis plan and endpoints proposed by the Company were reviewed and accepted by the Division of Cardiovascular and Renal Products (“DcaRP”) of the FDA.
RVXCF RVX

 
Resverlogix Announces Withdrawal of Public Offering of Units

2018-06-08 globenewswire
CALGARY, Alberta, June 08, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has opted not to proceed with the public offering of units of the Company announced on April 17, 2018, based on the Company’s assessment that market conditions are not currently conducive for a public offering on terms that would be in the best interests of the Company and its shareholders.
RVXCF RVX

 
Resverlogix 強調具備潛有將 Apabetalone 發展為一種通過“激活並殺死”方法根除 HIV-1 的治療藥物

2018-06-08 globenewswire
艾伯塔卡爾加里和波士頓, June 08, 2018 (GLOBE NEWSWIRE) -- 基於最近有關Apabetalone 在根除人類免疫缺陷病毒(HIV-1) 方面潛在作用的調查發現,Resverlogix Corp.(下稱“Resverlogix”或“公司”)(TSX:RVX) 正尋求與現有相關方合作共同抗擊HIV-1。 《自然》(Nature)的《中國藥理學報》(Acta Pharmacologica Sinica)(2018) 0:1–13 中一篇名為《BET 布羅莫結構域抑製劑Apabetalone 通過病毒激活誘使潛伏HIV-1 儲主細胞的細胞凋亡》(“The BET bromodomain inhibitor apabetalone induces apoptosis of latent HIV-1 reservoir cells following viral reactivation”)的文章顯示,Apabetalone 能夠揭露和激活潛伏HIV-1 儲主、誘使HIV-1 潛伏細胞死亡,並降低標準療法(cART 抗逆轉錄病毒聯合療法)的副作用。
83GK 84GK RVXCF RVX

 
Resverlogix 强调具备潜力将 Apabetalone 发展为一种通过“激活并杀死”的方法根除 HIV-1 的治疗药物

2018-06-08 globenewswire
艾伯塔卡尔加里和波士顿, June 08, 2018 (GLOBE NEWSWIRE) -- 基于最近有关Apabetalone 在根除人类免疫缺陷病毒(HIV-1) 方面潜在作用的调查发现,Resverlogix Corp.(下称“Resverlogix”或“公司”)(TSX:RVX) 正寻求与现有相关方合作共同抗击HIV-1。 《自然》(Nature)的《中国药理学报》(Acta Pharmacologica Sinica)(2018) 0:1–13 中一篇名为《BET 布罗莫结构域抑制剂Apabetalone 通过病毒激活诱使潜伏HIV-1 储主细胞的细胞凋亡》(“The BET bromodomain inhibitor apabetalone induces apoptosis of latent HIV-1 reservoir cells following viral reactivation”)的文章显示,Apabetalone 能够揭露和激活潜伏HIV-1 储主、诱使HIV-1 潜伏细胞死亡,并降低标准疗法(cART 抗逆转录病毒联合疗法)的副作用。
83GK 84GK RVXCF RVX

 
Resverlogix Highlights Potential to Develop Apabetalone as a Therapeutic for HIV-1 Eradication Utilizing the “Shock and Kill” Approach

2018-06-07 globenewswire
CALGARY, Alberta and BOSTON, June 07, 2018 (GLOBE NEWSWIRE) -- Based on recent findings on apabetalone’s potential role in human immunodeficiency virus (“HIV-1”) eradication, Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is seeking a partnership with an existing stakeholder in the ongoing fight against HIV-1. The most recent publication titled: “The BET bromodomain inhibitor apabetalone induces apoptosis of latent HIV-1 reservoir cells following viral reactivation,” in Nature’s Acta Pharmacologica Sinica (2018) 0:1–13; demonstrated apabetalone’s abilities to expose and reactivate latent HIV-1 reservoirs, induce HIV-1 latent cell death, and reduce the side effects of standard of care (cART combination antiretroviral therapy).
83GK 84GK RVXCF RVX

 
Resverlogix Closes US$30 Million Loan

2018-05-07 globenewswire
CALGARY, Alberta, May 07, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has closed the previously announced US$30 million senior secured loan (the “Loan”) with Third Eye Capital.
RVXCF RVX

 
Resverlogix Advances US$30 Million Loan Closing Documentation

2018-05-01 globenewswire
CALGARY, Alberta, May 01, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to update the market today that it is in the final stages of closing documentation in respect of the previously-announced US$30 million senior secured loan (the “Loan”) with Third Eye Capital, one of Canada’s largest alternative lending firms, acting as agent for a syndicate of lenders (the “Lenders”).
RVXCF RVX

 
Resverlogix Announces Proposed Offering of Units

2018-04-17 globenewswire
CALGARY, Alberta, April 17, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has filed a preliminary short form prospectus with the securities regulatory authorities in the provinces of Alberta, British Columbia and Ontario in connection with a proposed marketed offering of units of the Company (“Units”), comprised of common shares and common share purchase warrants (the “Offering”).
RVXCF RVX

 
Resverlogix Announces US$30 Million Loan Commitment Letter

2018-04-11 globenewswire
CALGARY, Alberta, April 11, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce today that it has accepted a commitment letter for a US$30 million senior secured loan (the “Loan”) with Third Eye Capital, one of Canada’s largest alternative lending firms, acting as agent for a syndicate of lenders (the “Lenders”). The Loan will have a term of 12 months, be repayable in part or in whole at any time, require payment of commitment and exit fees totaling US$1.
RVXCF RVX

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TSX:RVX / Resverlogix Corp. on message board site Silicon Investor.

Oravax(orvx) Oravax(orvx) Oravax(orvx)